GR3032207T3 - 2-Bromomelatonin in the therapy of sleep disorders - Google Patents

2-Bromomelatonin in the therapy of sleep disorders

Info

Publication number
GR3032207T3
GR3032207T3 GR990403294T GR990403294T GR3032207T3 GR 3032207 T3 GR3032207 T3 GR 3032207T3 GR 990403294 T GR990403294 T GR 990403294T GR 990403294 T GR990403294 T GR 990403294T GR 3032207 T3 GR3032207 T3 GR 3032207T3
Authority
GR
Greece
Prior art keywords
bromomelatonin
therapy
sleep disorders
pharmaceutical compositions
therapeutically effective
Prior art date
Application number
GR990403294T
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stanvok
Strambi Luigi Ferini
Original Assignee
Franco Fraschini
Stankov Bojidar
I F L O Istituto Farmacologico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Franco Fraschini, Stankov Bojidar, I F L O Istituto Farmacologico filed Critical Franco Fraschini
Publication of GR3032207T3 publication Critical patent/GR3032207T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GR990403294T 1991-05-13 1999-12-21 2-Bromomelatonin in the therapy of sleep disorders GR3032207T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
EP92107865A EP0513702B1 (en) 1991-05-13 1992-05-11 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Publications (1)

Publication Number Publication Date
GR3032207T3 true GR3032207T3 (en) 2000-04-27

Family

ID=11359886

Family Applications (2)

Application Number Title Priority Date Filing Date
GR960403498T GR3022060T3 (en) 1991-05-13 1996-12-17 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
GR990403294T GR3032207T3 (en) 1991-05-13 1999-12-21 2-Bromomelatonin in the therapy of sleep disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR960403498T GR3022060T3 (en) 1991-05-13 1996-12-17 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Country Status (9)

Country Link
US (1) US5430029A (el)
EP (2) EP0713701B1 (el)
JP (1) JPH05155769A (el)
AT (2) ATE142877T1 (el)
DE (2) DE69213814T2 (el)
DK (2) DK0713701T3 (el)
ES (2) ES2139132T3 (el)
GR (2) GR3022060T3 (el)
IT (1) IT1251544B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190490T1 (de) * 1990-09-28 2000-04-15 I F L O S A S Di Giorgio E Ald Kontrazeptives und menstruationszyklus regulierendes präparat mit onkostatischen eigenschaften
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5763471A (en) * 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AP2001002245A0 (en) * 1999-02-05 2001-09-30 Univ Manchester Regulation of anesthesia.
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
WO2005060968A1 (en) * 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
WO2005084664A1 (ja) * 2004-03-08 2005-09-15 Kanazawa University Technology Licensing Organization Ltd. インドール誘導体及びその用途
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
JP2025526852A (ja) * 2022-02-16 2025-08-15 ラ ファーマテック インコーポレイテッド 不眠症の治療のための新規医薬組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
FI900801A7 (fi) * 1987-08-17 1990-02-16 Nelson Res & Development Co Melantoniinianalogit

Also Published As

Publication number Publication date
DE69230046T2 (de) 2000-05-31
DE69213814D1 (de) 1996-10-24
ATE142877T1 (de) 1996-10-15
ES2139132T3 (es) 2000-02-01
IT1251544B (it) 1995-05-17
DE69230046D1 (de) 1999-10-28
DK0713701T3 (da) 2000-04-03
US5430029A (en) 1995-07-04
EP0713701B1 (en) 1999-09-22
ITMI911299A0 (it) 1991-05-13
EP0513702A2 (en) 1992-11-19
ITMI911299A1 (it) 1992-11-13
ATE184792T1 (de) 1999-10-15
DK0513702T3 (da) 1996-12-30
EP0513702B1 (en) 1996-09-18
EP0713701A1 (en) 1996-05-29
JPH05155769A (ja) 1993-06-22
GR3022060T3 (en) 1997-03-31
ES2093735T3 (es) 1997-01-01
DE69213814T2 (de) 1997-04-03
EP0513702A3 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
GR3022060T3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
KR100321467B1 (el)
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
TW272940B (en) /
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
EP0494972A4 (en) Effervescent dosage form and method of administering same
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
EP0342055A3 (en) Treatment of skin disorders
IL76561A (en) Pharmaceutical compositions containing ifn-ypsilon for the treatment of rheumatic diseases
IL86302A0 (en) Pharmaceutical combination for the prophylaxis and therapy of malaria
IL111580A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
IL106751A0 (en) Pharmaceutical compositions for the treatment of reversible obstructive airways diseases
EP0564216A3 (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ZA925983B (en) Pharmaceutical compositions for the treatment of skin disorders
GB9413939D0 (en) Pharmaceutical composition for the treatment of chronic skin ulcers
CS123992A3 (en) Liquid pharmaceutical composition which is administered in the form of afoam
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi